Kommentar zur Hormonersatztherapie – Ergänzung zur DGGG-Stellungnahme zur Lancet-Studie „Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence“ (29. August 2019)